; Angiotech Pharma Acquires Product Candidates and Technology Assets from Haemacure Corporation
Documents
Resources
Learning Center
Upload
Plans & pricing Sign in
Sign Out
Your Federal Quarterly Tax Payments are due April 15th Get Help Now >>

Angiotech Pharma Acquires Product Candidates and Technology Assets from Haemacure Corporation

VIEWS: 106 PAGES: 6

Angiotech Pharma Acquires Product Candidates and Technology Assets from Haemacure Corporation Summary Angiotech Pharmaceuticals, Inc. a specialty pharmaceutical and medical device company, announced the closing of its acquisition of certain product candidates and technology assets of Haemacure Corporation. Haemacure has been involved in proceedings under Canada’s Bankruptcy and Insolvency Act and Chapter 11 of the US Bankruptcy Code. Through an asset sale transaction, Angiotech has acquired all of the relevant research and development activities, manufacturing operations, key personnel, and intellectual property rights necessary to pursue the commercialization of Haemacure’s human biomaterial product candidates, namely, fibrin sealant and thrombin hemostat. According to GlobalData the rationale behind this transaction stems from the high opportunity and value that Angiotech could gain from entering the wound care market and the complementing product portfolios the transaction would bring along. Scope Details of the deal included - History of previous deals or agreements between the two companies - Rationale behind the deal - Forecast market revenue for the global wound closure devices market - Details of the acquired products in question Reasons to buy - Identify key M&A trends in the medical equipment market - Track competitor product portfolios and acquisition history - Assess future outlook of the company

More Info
  • pg 1
									                  Angiotech Pharma Acquires Product Candidates and
                   Technology Assets from Haemacure Corporation
      Reference Code: GDME0012M&A                                                                                                 Publication Date: April 2010

      1         Table of Contents                                                           2        Angiotech Pharma Acquires Product
      1   Table of Contents ..........................................................1              Candidates and Technology Assets from
        1.1   List of Tables ..........................................................1             Haemacure Corporation
        1.2   List of Figures.........................................................1
      2 Angiotech Pharma Acquires Product Candidates and                                    2.1      What is this Report About?
      Technology Assets from Haemacure Corporation ................1
        2.1   What is this Report About?.....................................1              GlobalData’s dedicated research and analysis team exhaustively
        2.2   Deal Background....................................................1          researched and evaluated the acquisition of lead product
        2.3   Deal Rationale........................................................2       candidates and technology assets of Haemacure Corporation by
        2.4   The Acquired Products...........................................3             Angiotech Pharma. The rationale of the deal was evaluated by the
      3 Appendix .......................................................................4
                                                                                            team, based on a close study of each of the company’s products,
        3.1   Research Methodology ..........................................4
        3.2   Coverage................................................................5     intellectual property and the general market trends, market
        3.3   Secondary Research..............................................5             revenues in the wound care market in the US and Europe.
        3.4   Primary Research...................................................5
        3.5   Models....................................................................5   2.1.1      Deal Details
        3.6   Forecasts ...............................................................5    Angiotech Pharmaceuticals, Inc. (NASDAQ: ANPI, TSX: ANP), a
        3.7   Expert Panels .........................................................6      specialty pharmaceutical and medical device company, announced
        3.8   GlobalData Consulting ...........................................6
                                                                                            the closing of its acquisition of certain product candidates and
        3.9   Contact Us .............................................................6
        3.10     Disclaimer..........................................................6      technology assets of Haemacure Corporation (“Haemacure”).
                                                                                            Haemacure has been involved in proceedings under Canada’s
                                                                                            Bankruptcy and Insolvency Act and Chapter 11 of the United
                                                                                            States Bankruptcy Code. Through an asset sale transaction,
      1.1      List of Tables                                                               Angiotech has acquired all of the relevant research and
      Table 1: Wound Closure Devices Market, Global, Revenue                                development activities, manufacturing operations, key personnel,
                 ($m), 2009 – 2016      3                                                   and intellectual property rights necessary to pursue the
      Table 2: Hemaseel Thrombin Haemostatic Agent Product                                  commercialization of Haemacure’s human biomaterial product
                 Details        4                                                           candidates, namely, fibrin sealant and thrombin hemostat. The
      Table 3: Hemaseel HMN fibrin sealant-Adhesion Prevention,
                 Product Details        4                                                   proprietary fibrin sealant is made of two human plasma proteins,
      Table 4: Hemaseel HMN fibrin sealant-Hemostatis, Product                              fibrinogen and thrombin, which are extracted from human blood
                 Details        4                                                           plasma through a proprietary, high-yield, low-cost extraction
                                                                                            process.

      1.2      List of Figures                                                              2.2      Deal Background
      Figure 1:   Wound Closure Market, Global, Revenue ($m),                               Angiotech Pharmaceuticals, Inc. in 2009 made a collaborative
                  2009 – 2016 2                                                             transaction with Haemacure Corporation related to Haemacure’s
      Figure 2: GlobalData Methodology 4
                                                                                            proprietary fibrin and thrombin technologies, both of which are
                                                                                            currently in development. As part of this collaboration, Angiotech
                                                                                            had agreed to provide to Haemacure a senior secured bridge
                                                                                            financing facility of US$2.5 million, with the option for Angiotech to
                                                                                            invest an additional US$1 million in the facility. The collabor
								
To top